Voyager Applications
ACE® Breast Reconstruction
The Problem
Soft-tissue reinforcement is critical in reconstructive breast surgery after mastectomy. Existing biologic grafts dominate the $600M market, expected to reach $1B by 2034, but they are costly and limit access, especially in public systems and emerging markets.
Read More
Current Solutions
Galaflex® (Tepha/BD), a scaffold made from PH4B, proved the value of resorbable scaffolds and grew to $50M annual sales in just 3 years, However, it remains expensive to produce.
Our Solution
More Applications
Connect with us
Join us in shaping the future of medtech